(S)-1-Boc-2-苄基哌嗪 | 169447-86-3

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (S)-1-Boc-2-苄基哌嗪
• 中文别名: (S)-2-苄基哌嗪-1-甲酸叔丁酯；(S)-1-BOC-2-苯基哌嗪；(S)-2-苄基-1-BOC-哌嗪；(S)-1-N-BOC-2-苄基哌嗪；(S)-2-苄基-1-Boc-哌嗪
• 英文名称: (S)-N¹-Boc-2-benzylpiperazine
• 英文别名: tert-butyl (S)-2-benzylpiperazine-1-carboxylate；(S)-1-Boc-2-benzylpiperazine；(S)-N-Boc-2-benzylpiperazine；2(S)-benzyl-1-tert-butoxycarbonylpiperazine；tert-butyl (2S)-2-benzylpiperazine-1-carboxylate
• CAS: 169447-86-3
• 化学式: C₁₆H₂₄N₂O₂
• 分子量: 276.379
• InChiKey: QKUHUJCLUFLGCI-AWEZNQCLSA-N

物化性质

• 沸点：
  382.9±17.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(S)-1-Boc-2-benzylpiperazine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(S)-1-Boc-2-benzylpiperazine
Ingredient name:
CAS number: 169447-86-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C16H24N2O2
Molecular weight: 276.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

(S)-1-Boc-2-苄基哌嗪是合成许多药物的重要中间体。其制备方法如下：将带有搅拌装置的三口烧瓶中加入2-苄基哌嗪和由碳酸钠与碳酸氢钠组成的缓冲溶液（200 mL），并在冰浴条件下，通过滴液漏斗缓慢滴加二碳酸叔丁酯，并在30℃水浴中搅拌反应22小时。反应完成后，使用乙醚（100 mL×2）萃取出未反应的二碳酸叔丁酯，将剩余的水相用3 mol/L盐酸调节pH值至2-3，随后用乙酸乙酯（100 mL×4）进行萃取。接着使用无水硫酸钠干燥有机相，过滤并利用旋转蒸发仪去除溶剂，最终得到无色油状物液体(S)-1-Boc-2-苄基哌嗪。

反应信息

• 作为反应物：
  描述：

  (S)-1-Boc-2-苄基哌嗪 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  哒嗪基支架的合成为α-螺旋模拟物。

  摘要：

  描述了几种模仿肽α-螺旋的i，i + 3或i + 4和i + 7残基呈递的两亲，非肽支架。该方法使用哒嗪核心，合成过程仅涉及几个步骤，并最大程度地减少了形成CC键的反应。合成的多功能性使其适合于制备低分子量的α-螺旋模拟物的小型文库，这些文库可能针对某些蛋白质/蛋白质相互作用。

  DOI：

  10.1021/ol701487g
• 作为产物：
  描述：

  (S)-1,3-二苄基哌嗪 在 palladium 10% on activated carbon 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 30.0h， 生成 (S)-1-Boc-2-苄基哌嗪
  参考文献：
  名称：

  从容易获得的α-氨基酸 有效地一锅法合成对映体纯的N保护的α-取代的哌嗪†

  摘要：

  从市售的N-保护的氨基酸开始，已开发出一条新的途径，以对映体纯的3-取代的带有苄基保护基的哌嗪，总收率良好（83-92％）。该方法代表了一种有效且简单的一锅法，采用了由Ugi-4组分反应，Boc脱保护，分子内环化反应和最终还原（UDCR）组成的合成序列。因此，还可以通过相应的哌嗪的简单保护和脱保护步骤，从苄基保护的前体中获得带有Boc保护基的2-取代的哌嗪。证明了该方法的实际实用性用于手性药物合成。

  DOI：

  10.1039/c7nj04039c
• 作为试剂：
  描述：

  (S)-tert-butyl 2,4-dibenzylpiperazine-1-carboxylate 在 钯 (S)-1-Boc-2-苄基哌嗪 作用下， 生成 (S)-1-Boc-2-苄基哌嗪
  参考文献：
  名称：

  Inhibitors of farnesyl-protein transferase

  摘要：

  本发明涉及抑制法尼酰蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼酰化的化合物。本发明还涉及包含本发明化合物的化疗组合物以及抑制法尼酰蛋白转移酶和致癌基因蛋白Ras的方法。式A的化合物代表本发明的化合物：##STR1##

  公开号：

  US05736539A1

文献信息

• Therapeutic Piperazines
  申请人：Keenan P. Terrence

  公开号：US20070203124A1

  公开（公告）日：2007-08-30

  The invention includes a compound of formula I: wherein R 1 , X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in animals.

  该发明包括式I的化合物： 其中R 1 ，X，Z，n和m具有本文所述的任何值，以及这些化合物的盐，包含这些化合物的组合物，以及包括给予这些化合物的治疗方法。这些化合物是PDE4功能的抑制剂，对于改善动物的认知功能是有用的。
• IL-17 Ligands And Uses Thereof
  申请人：DICE Molecules SV LLC.

  公开号：US20200247785A1

  公开（公告）日：2020-08-06

  Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.

  本文提供了新型配体及其药物组合物，可调节IL-17A。还提供了制备IL-17A调节剂的方法。这些化合物可能在治疗和/或预防炎症、癌症或自身免疫疾病等方面有用。
• [EN] THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C<br/>[FR] INHIBITEURS DE TYPE THIÉNOPYRIMIDINE DE PROTÉINES KINASES C ATYPIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2013078126A1

  公开（公告）日：2013-05-30

  The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X如本文所定义。式（I）的化合物及其盐具有PKC抑制活性，并可用于治疗增生性疾病。
• [EN] PYRIDAZINE BASED ALPHA-HELIX MIMETICS<br/>[FR] STRUCTURES MIMÉTIQUES À HÉLICE ALPHA À BASE DE PYRIDAZINE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2009025751A1

  公开（公告）日：2009-02-26

  The synthesis of new α-helix scaffolds mimicking i, i+3 or i+4, i+7 residues, was accomplished. The common pyridazine heterocycle originates from the easily available building block, 6. These scaffolds may be thought of as synthetic counterparts of amphiphilic α-helices having a 'wet face' along one side and a hydrophobic face along the other side of the helix.

  成功合成了模仿i，i+3或i+4，i+7残基的新α-螺旋支架。常见的吡嗪杂环来自易得的6号构建块。这些支架可以被看作是具有“湿面”和“疏水面”的两侧的合成对应物。
• [EN] INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE<br/>[FR] INHIBITEURS DE FARNESYL-PROTEINE TRANSFERASE
  申请人：MERCK & CO., INC.

  公开号：WO1996030343A1

  公开（公告）日：1996-10-03

  (EN) The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.(FR) La présente invention concerne des composés qui inhibent la farnésyl-protéine transférase (FTase) et la farnélysation de l'oncogène Ras protéique. L'invention concerne en outre des compositions chimiothérapeutiques contenant les composés de cette invention, et des procédés servant à inhiber la farnésyl-protéine transférase et la farnélysation de la protéine d'oncogène Ras.

  该发明涉及抑制法尼酰-蛋白转移酶（FTase）和癌基因蛋白Ras的法尼酰化的化合物。该发明进一步涉及含有该发明化合物的化疗组合物和抑制法尼酰-蛋白转移酶和癌基因蛋白Ras的法尼酰化的方法。